These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 6452910)
21. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Weeks RA; Piccini P; Harding AE; Brooks DJ Ann Neurol; 1996 Jul; 40(1):49-54. PubMed ID: 8687191 [TBL] [Abstract][Full Text] [Related]
22. Reduction of 3H-kainic acid binding in rat cerebral cortex by chronic methamphetamine administration. Kashiwabara K; Sato M; Otsuki S Biol Psychiatry; 1984 Aug; 19(8):1173-82. PubMed ID: 6093902 [TBL] [Abstract][Full Text] [Related]
23. Second messenger systems in brains of patients with Parkinson's or Huntington's disease. Tanaka C; Nishino N; Hashimoto T; Kitamura N; Yoshihara C; Saito N Adv Neurol; 1993; 60():175-80. PubMed ID: 8093576 [TBL] [Abstract][Full Text] [Related]
24. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea. Huot P; Lévesque M; Parent A Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832 [TBL] [Abstract][Full Text] [Related]
26. Expression of the receptor for advanced glycation end products in Huntington's disease caudate nucleus. Ma L; Nicholson LF Brain Res; 2004 Aug; 1018(1):10-7. PubMed ID: 15262199 [TBL] [Abstract][Full Text] [Related]
27. Dopamine and noradrenaline in post-mortem brain in Huntington's disease and schizophrenic illness. Bird ED; Spokes EG; Iversen LL Acta Psychiatr Scand Suppl; 1980; 280():63-73. PubMed ID: 6447433 [No Abstract] [Full Text] [Related]
28. Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study. Peinemann A; Schuller S; Pohl C; Jahn T; Weindl A; Kassubek J J Neurol Sci; 2005 Dec; 239(1):11-9. PubMed ID: 16185716 [TBL] [Abstract][Full Text] [Related]
29. Properties of [3H]AMPA binding in postmortem human brain from psychotic subjects and controls: increases in caudate nucleus associated with suicide. Freed WJ; Dillon-Carter O; Kleinman JE Exp Neurol; 1993 May; 121(1):48-56. PubMed ID: 7684336 [TBL] [Abstract][Full Text] [Related]
30. Functional MRI study of a serial reaction time task in Huntington's disease. Kim JS; Reading SA; Brashers-Krug T; Calhoun VD; Ross CA; Pearlson GD Psychiatry Res; 2004 May; 131(1):23-30. PubMed ID: 15246452 [TBL] [Abstract][Full Text] [Related]
31. Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease. Furtado S; Suchowersky O; Rewcastle B; Graham L; Klimek ML; Garber A Ann Neurol; 1996 Jan; 39(1):132-6. PubMed ID: 8572659 [TBL] [Abstract][Full Text] [Related]
32. Discrimination and pharmacological characterization of I2-imidazoline sites with [3H]idazoxan and alpha-2 adrenoceptors with [3H]RX821002 (2-methoxy idazoxan) in the human and rat brains. Miralles A; Olmos G; Sastre M; Barturen F; Martin I; Garcia-Sevilla JA J Pharmacol Exp Ther; 1993 Mar; 264(3):1187-97. PubMed ID: 8095548 [TBL] [Abstract][Full Text] [Related]
33. Sulfonylurea binding sites in normal human brain and in Parkinson's disease, progressive supranuclear palsy and Huntington's disease. Holemans S; Javoy-Agid F; Agid Y; De Paermentier F; Laterre EC; Maloteaux JM Brain Res; 1994 Apr; 642(1-2):327-33. PubMed ID: 8032896 [TBL] [Abstract][Full Text] [Related]
34. Regional specificity of brain atrophy in Huntington's disease. Halliday GM; McRitchie DA; Macdonald V; Double KL; Trent RJ; McCusker E Exp Neurol; 1998 Dec; 154(2):663-72. PubMed ID: 9878201 [TBL] [Abstract][Full Text] [Related]
35. Autoradiographic localization of high-affinity [3H]kainic acid binding sites in the rat forebrain. Unnerstall JR; Wamsley JK Eur J Pharmacol; 1983 Jan; 86(3-4):361-71. PubMed ID: 6299756 [TBL] [Abstract][Full Text] [Related]
36. Phylogenetic distribution of [3H]kainic acid receptor binding sites in neuronal tissue. London ED; Klemm N; Coyle JT Brain Res; 1980 Jun; 192(2):463-76. PubMed ID: 6247025 [TBL] [Abstract][Full Text] [Related]
37. NMDA receptor losses in putamen from patients with Huntington's disease. Young AB; Greenamyre JT; Hollingsworth Z; Albin R; D'Amato C; Shoulson I; Penney JB Science; 1988 Aug; 241(4868):981-3. PubMed ID: 2841762 [TBL] [Abstract][Full Text] [Related]
39. Decrease of mGluR5 receptor density goes parallel with changes in enkephalin and substance P immunoreactivity in Huntington's disease: a preliminary investigation in the postmortem human brain. Gulyás B; Sovago J; Gomez-Mancilla B; Jia Z; Szigeti C; Gulya K; Schumacher M; Maguire RP; Gasparini F; Halldin C Brain Struct Funct; 2015 Sep; 220(5):3043-51. PubMed ID: 24969128 [TBL] [Abstract][Full Text] [Related]
40. Increased [3H]kainic acid binding in the prefrontal cortex in schizophrenia. Nishikawa T; Takashima M; Toru M Neurosci Lett; 1983 Oct; 40(3):245-50. PubMed ID: 6646495 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]